克拉斯
癌症研究
突变
医学
生物标志物
肺癌
基因突变
原发性肿瘤
肿瘤科
基因
癌症
内科学
生物
转移
结直肠癌
遗传学
作者
Cheng‐Bo Han,Jie‐Tao Ma,Jianzhu Zhao,Yang Zhou,Wei Jing,Huawei Zou
标识
DOI:10.3109/07357907.2011.621914
摘要
A meta-analysis was performed to determine EGFR mutations, gene amplification, and protein expression and KRAS mutations in primary and metastatic nonsmall cell lung cancer (NSCLC). We found that KRAS gene mutation frequencies were higher in primary than in metastatic tumors. There was no significant difference in EGFR mutation frequency between the primary and metastatic tumors. These results suggest that KRAS mutations in primary NSCLC foci may be a more accurate biomarker than in metastases to reflect KRAS mutation status. Combined detection of EGFR and KRAS mutations in primary NSCLC foci appears to be an optimal approach for first-line EGFR-TKI therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI